Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.52 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.43 |
| ▸ | CDC37 | Q16543 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142204 | 0.86 | HSP90AA1 (0.50) | HSP90AA1CDC37 | |
| SCHEMBL4991999 | 0.86 | HSP90AA1 (0.50) | HSP90AA1CDC37 | |
| SCHEMBL4146277 | 0.84 | HSP90AA1 (0.53) | HSP90AA1CDC37 | |
| SCHEMBL1743367 | 0.84 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1CDC37 | |
| SCHEMBL1744449 | 0.84 | HSP90AA1 (0.57) | HSP90AA1HSP90B1CDC37 | |
| SCHEMBL4896589 | 0.84 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1CDC37 | |
| SCHEMBL4997714 | 0.83 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1CDC37 | |
| SCHEMBL11980469 | 0.83 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL1745214 | 0.77 | HSP90AA1 (0.52) | HSP90AA1HSP90B1CDC37 | |
| SCHEMBL16190149 | 0.74 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1TRAP1CDC37 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315929-A1 | HSP90 COMBINATION THERAPY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-10-23 | — | — | US | disclosed |
| US-8017780-B1 | Therapeutic compounds and uses thereof | MYREXIS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017780-B1 | Therapeutic compounds and uses thereof | MYREXIS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017780-B1 | Therapeutic compounds and uses thereof | MYREXIS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315929-A1 | HSP90 COMBINATION THERAPY | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885TRAP1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.